{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"322"},{"groupId":"OG001","value":"323"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"196"}]}],"title":"Serious adverse events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"324"}],"units":"Participants"}],"description":"An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not.\n\nA serious adverse event (SAE) is any untoward medical occurrence that, at any dose:\n\n* Resulted in death\n* Was life-threatening\n* Required hospitalization or prolongation of existing hospitalization\n* Resulted in disability/incapacity\n* Resulted in a congenital anomaly/birth defect\n* Was considered a significant medical AE by the investigator based on medical judgment","groups":[{"description":"Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG000","title":"Zanubrutinib"},{"description":"Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG001","title":"Ibrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Analysis Set includes all participants who received any dose of study drug.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.","title":"Number of Participants With Treatment-emergent Adverse Events (TEAE)","type":"SECONDARY","unitOfMeasure":"Participants"}